ARCA biopharma to get US patent for ways of heart failing treatment with genetic tests based bucindolol ARCA biopharma, Inc uk pharmacy . , a biopharmaceutical company developing genetically targeted therapies for heart failing and other cardiovascular diseases, today announced that it offers received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Once issued, the patent will provide coverage for methods of treating heart failure patients with bucindolol predicated on genetic testing. Bristow, President and CEO of ARCA. .
Pacitti, Pharm.D., M.B.A., Magee Rehabilitation Medical center, Philadelphia, PA Lois F. Parker, B.S.Pharm., Massachusetts General Hospital Department of Pharmacy, Boston, MA Mary H. Parker, Pharm.D., BCPS-AQ Cardiology, FCCP, Durham Veterans Affairs Medical Center, Durham, NC Christina W. Quillian, Pharm.D., BCPS, Edward Hines Jr. Veterans Affairs Hospital, Hines, IL Suzie Schrater, Pharm.D., M.P.H., VHA, Performance Providers; Mid-America Provider Solutions, Valley Center, KS James D. Scott, Pharm.D., M.Ed., AAHIVP, FCCP, Western University of Health Sciences, Pomona, CA Victoria A. Serrano Adams, Pharm.D., FCSHP, University of California SAN FRANCISCO BAY AREA Medical Center, San Francisco, CA Linda M. Spooner, Pharm.D., BCPS, MCPHS University, Worcester, MA Amy L.